Anthony A. Bavry, MD, MPH; John H. Chiu, MD; Brian K. Jefferson, MD; Juhana Karha, MD; Deepak L. Bhatt, MD; Stephen G. Ellis, MD; Patrick L. Whitlow, MD
Potential Financial Conflicts of Interest: Consultancies: D.L. Bhatt (AstraZeneca, Bristol-Myers Squibb, Centocor, Daiichi Sankyo, Eisai, Eli Lilly Inc., GlaxoSmithKline, Millenium, Otsuka, ParinGenix, PDL BioPharma, Sanofi-Aventis, Schering-Plough, The Medicines Company), S.G. Ellis (Boston Scientific, Celera Diagnostics, Cordis, Viacor); Honoraria: A.A. Bavry (Genesis), D.L. Bhatt (AstraZeneca, Bristol-Myers Squibb, Centocor, Daiichi Sankyo, Eisai, Eli Lilly Inc., GlaxoSmithKline, Millenium, Otsuka, ParinGenix, PDL BioPharma, Sanofi-Aventis, Schering-Plough, The Medicines Company); Grants received: D.L. Bhatt (Bristol-Myers Squibb, Sanofi-Aventis, Eisai, The Medicines Company); P.L. Whitlow (Abbott, Boston Scientific, Cordis, Edwards Lifesciences, Evalve Inc., ev3 Inc.). Dr. Whitlow is an advisor and member of the board of directors for ICON Interventional Systems and Medilogics, and Dr. Bhatt has served on speakers' bureaus for Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company.
Bavry AA, Chiu JH, Jefferson BK, Karha J, Bhatt DL, Ellis SG, et al. Development of Coronary Aneurysm after Drug-Eluting Stent Implantation. Ann Intern Med. ;146:230–232. doi: 10.7326/0003-4819-146-3-200702060-00146
Download citation file:
Published: Ann Intern Med. 2007;146(3):230-232.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use